Efficacy of Glycicumarin and Isoliquiritigenin in Suppressing Colonic Peristalsis in Both an Animal Model and a Clinical Trial-Reference-Cited by-同舟云学术

Efficacy of Glycicumarin and Isoliquiritigenin in Suppressing Colonic Peristalsis in Both an Animal Model and a Clinical Trial

Published:2024-02-06 Issue:2 Volume:47 Page:373-382
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Kobayashi Reo¹,Inoue Ken¹,Sugino Satoshi¹²,Hirose Ryohei¹,Doi Toshifumi¹,Harusato Akihito¹,Dohi Osamu¹,Yoshida Naohisa¹,Uchiyama Kazuhiko¹,Ishikawa Takeshi¹,Takagi Tomohisa¹,Konishi Hideyuki¹,Hirai Yasuko³,Mizushima Katsura³,Naito Yuji³,Itoh Yoshito¹

Affiliation:

1. Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine

2. Department of Gastroenterology and Hepatology, Asahi University Hospital

3. Department of Human Immunology and Nutrition Science, Kyoto Prefectural University of Medicine

Publisher

Pharmaceutical Society of Japan

Link

https://www.jstage.jst.go.jp/article/bpb/47/2/47_b23-00680/_pdf

Reference38 articles.

1. 1) Fukudo S, Okumura T, Inamori M, Okuyama Y, Kanazawa M, Kamiya T, Sato K, Shiotani A, Naito Y, Fujikawa Y, Hokari R, Masaoka T, Fujimoto K, Kaneko H, Torii A, Matsueda K, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J. Gastroenterol., 56, 193–217 (2021).

2. 2) Mizukami T, Sugimoto S, Masaoka T, Suzuki H, Kanai T. Colonic dysmotility and morphological abnormality frequently detected in Japanese patients with irritable bowel syndrome. Intest. Res., 15, 236–243 (2017).

3. 3) Inoue K, Okuda T, Oka K, Sugino S, Endo Y, Ota T, Minagawa Y, Yasue C, Tsuji T, Katayama T, Nakamura H, Nagata A, Komaki T, Naito Y, Itoh Y, Kagawa K. Effects of L-menthol and carbon dioxide on the adenoma detection rate during colonoscopy: L-menthol and carbon dioxide on colonoscopy. Digestion, 101, 323–331 (2020).

4. 4) Study Group of the diagnosis and treatment of chronic diarrhea. Guidelines for chronic diarrhea in 2023. Nankodo, Tokyo, Japan, p. 49 (2023).

5. 5) Oka T, Okumi H, Nishida S, Ito T, Morikiyo S, Kimura Y, Murakami M. Effects of Kampo on functional gastrointestinal disorders. Biopsychosoc Med., 8, 5 (2014).